Dashboard
1
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of 24.29% and Operating profit at 13.72% over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 5.07% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 24.29% and Operating profit at 13.72% over the last 5 years
3
Flat results in Mar 26
Stock DNA
Pharmaceuticals & Biotechnology
CNY 1,524 Million (Mid Cap)
48.00
NA
0.00%
0.32
6.90%
0.80
Revenue and Profits:
Net Sales:
405 Million
(Quarterly Results - Mar 2026)
Net Profit:
-17 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
48.8%
0%
48.8%
6 Months
144.61%
0%
144.61%
1 Year
191.97%
0%
191.97%
2 Years
261.68%
0%
261.68%
3 Years
100.37%
0%
100.37%
4 Years
74.24%
0%
74.24%
5 Years
0%
0%
0.0%
Wuhan Huakang Century Medical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
24.29%
EBIT Growth (5y)
13.72%
EBIT to Interest (avg)
28.02
Debt to EBITDA (avg)
1.45
Net Debt to Equity (avg)
0.24
Sales to Capital Employed (avg)
0.69
Tax Ratio
16.79%
Dividend Payout Ratio
17.57%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.66%
ROE (avg)
5.07%
Valuation key factors
Factor
Value
P/E Ratio
48
Industry P/E
Price to Book Value
2.87
EV to EBIT
36.65
EV to EBITDA
30.64
EV to Capital Employed
2.45
EV to Sales
2.82
PEG Ratio
0.63
Dividend Yield
NA
ROCE (Latest)
6.69%
ROE (Latest)
5.99%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Bullish
Bullish
OBV
Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
405.50
292.30
38.73%
Operating Profit (PBDIT) excl Other Income
-9.80
-11.60
15.52%
Interest
8.60
8.80
-2.27%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-16.90
-28.00
39.64%
Operating Profit Margin (Excl OI)
-24.20%
-68.20%
4.40%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 38.73% vs 27.25% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 39.64% vs 12.77% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,280.10
1,701.60
34.00%
Operating Profit (PBDIT) excl Other Income
223.90
136.00
64.63%
Interest
42.90
23.60
81.78%
Exceptional Items
-0.00
0.80
-100.00%
Consolidate Net Profit
120.40
66.70
80.51%
Operating Profit Margin (Excl OI)
80.00%
53.10%
2.69%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 34.00% vs 6.46% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 80.51% vs -37.84% in Dec 2024
About Wuhan Huakang Century Medical Co., Ltd. 
Wuhan Huakang Century Medical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






